Legend Biotech Corporation (LEGN) Short-Term Debt to Capital

Symbol and logo of brand Legend Biotech Inc. (LEGN)

The visualized price action of Legend Biotech (LEGN) highlights the impact of laboratory expansion costs and drug sales rates, with the indicator standing at 0.13. The brand enjoys global recognition in oncology due to the quality of its biologics. Legend Biotech (LEGN) generates revenue from the commercialization of myeloma gene therapy through partnership contracts, utilizing advanced CAR receptors.

LEGN (Legend Biotech Inc.) Current Liabilities to Capital history from 07/04/2022 to 10/28/2026

Analytical breakdowns for Legend Biotech

- price and consensus price forecast:
Price Chart Legend Biotech Inc.|LEGN - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Legend Biotech Corp|LEGN - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Legend Biotech|LEGN - Total Stockholders' Equity|Market Value to Book Value Ratio legendbiotech.com|LEGN - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Legend Biotech|LEGN - Long-Term Liabilities to Capital|Short-Term Debt to Capital Legend Biotech Corporation|LEGN - Company Total Indebtedness|Debt to Book Value Legend Biotech Corp|LEGN - Long-Term Debt|Company Current Liabilities Legend Biotech
Fundamental company analysis:Legend Biotech Inc. (LEGN)
Manufactured products of legendbiotech.com

This ratio determines the share of short-term liabilities within the equity structure, measuring the company's ability to service current loans without compromising financial stability. By analyzing the trend of short-term accounts payable relative to equity, an investor can assess the liquidity of Legend Biotech (LEGN) amid the capital-intensive scaling of CAR-T therapy and regulatory pressure, which is critical for evaluating the issuer's solvency.

Competitors of Legend Biotech

Short-Term Debt to Equity Sana Bio SANA|Short-Term Debt to Capital Ratio Autolus Corp (AUTL)|Allogene Therapeutics - Short-Term Debt to Capital|selectabio.com - Short-Term Debt to Equity Ratio|CLLS (Cellectis Biotherapeutics) - Short-Term Debt to Equity|CRBU: Current Liabilities to Capital|Instil Bio, Inc (TIL) - Short-Term Debt to Equity|GNTA (Genenta Science) - Short-Term Debt to Equity|Short-Term Debt to Equity IPSC (Century Tx)|Current Liabilities to Capital Jasper Bio|SNTI: Short-Term Debt to Capital|Short-Term Indebtedness to Equity adaptimmune.com ADAP|CERO: Short-Term Debt to Equity Ratio|TCRT - Current Liabilities to Capital|Short-Term Debt to Equity Ratio Achilles Tx (ACHL)|CRGX - Ratio of Short-Term Indebtedness to Capital|PSTX (Poseida Therapeutics, Inc.) - Short-Term Debt to Capital|2seventy bio Inc. (TSVT) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital GRCL (Gracell Biotechnologies Ltd)